Eric H Bernicker, MD

Associate Professor of Clinical Medicine in Oncology, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Bernicker earned his medical degree from Baylor College of Medicine in Houston, TX in 1990. Subsequently, he completed his residency at Baylor Affiliated Hospitals and was chief medical resident at Ben Taub General Hospital from 1993–1994. Dr. Bernicker held a faculty appointment at Baylor College of Medicine as a clinical assistant professor from 1996–2012 before joining the Houston Methodist Cancer Center in January 2013, where he serves as director of Medical Thoracic Oncology. As a physician-scientist, Dr. Bernicker oversees the expansion of clinical trials at The Methodist Hospital relating to Thoracic Oncology with all stages of disease, a combination of SWOG trials, and industry trials of novel targeted agents. 

Description of Research

Dr. Bernicker’s research focuses on looking at different therapeutic approaches, such as targeted therapies and immunotherapies, in the treatment of lung cancer. By understanding how to identify patients at risk for relapse after surgery or those who can be spared the toxicities of chemotherapy, the immune system can be stimulated to preferentially destroy tumor cells, spare normal tissues, and improve patient survival along with the development of less toxic therapeutics. Eventually, the goal is to be able to offer new therapies and clinical trials to patients at Methodist with any stage of non-small cell lung cancer or small cell lung cancer.

Areas Of Expertise

Lung cancer Cancer research Targeted therapeutics
Education & Training

MD, Baylor College of Medicine
Residency, Baylor College of Medicine
Clinical Fellowship, Baylor College of Medicine
Internship, Dallas County Hospital -Parkland Memorial Hospital
Publications

Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma
Del C Monroig-Bosque, P, Driver, B, Morales-Rosado, JA, Deavers, M, Tacha, D, Bernicker, E, Cagle, PT & Miller, RA 2018, Archives of Pathology and Laboratory Medicine. DOI: 10.5858/arpa.2017-0516-OA

Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology
Lindeman, NI, Cagle, PT, Aisner, DL, Arcila, ME, Beasley, MB, Bernicker, EH, Colasacco, C, Dacic, S, Hirsch, FR, Kerr, K, Kwiatkowski, DJ, Ladanyi, M, Nowak, JA, Sholl, L, Temple-Smolkin, R, Solomon, B, Souter, LH, Thunnissen, E, Tsao, MS, Ventura, CB, Wynes, MW & Yatabe, Y 2018, Archives of Pathology and Laboratory Medicine, vol 142, no. 3, pp. 321-346. DOI: 10.5858/arpa.2017-0388-CP

Practice Patterns and Outcomes in Elderly Stage I Non-Small-cell Lung Cancer: A 2004 to 2012 SEER Analysis
Dalwadi, SM, Szeja, SS, Bernicker, EH, Butler, EB, Teh, BS & Farach, AM 2017, Clinical Lung Cancer. DOI: 10.1016/j.cllc.2017.11.004

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Lindeman, NI, Cagle, PT, Aisner, DL, Arcila, ME, Beasley, MB, Bernicker, E, Colasacco, C, Dacic, S, Hirsch, FR, Kerr, K, Kwiatkowski, DJ, Ladanyi, M, Nowak, JA, Sholl, L, Temple-Smolkin, R, Solomon, B, Souter, LH, Thunnissen, E, Tsao, MS, Ventura, CB, Wynes, MW & Yatabe, Y 2018, Journal of Molecular Diagnostics. DOI: 10.1016/j.jmoldx.2017.11.004

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Lindeman, NI, Cagle, PT, Aisner, DL, Arcila, ME, Beasley, MB, Bernicker, E, Colasacco, C, Dacic, S, Hirsch, FR, Kerr, K, Kwiatkowski, DJ, Ladanyi, M, Nowak, JA, Sholl, L, Temple-Smolkin, R, Solomon, B, Souter, LH, Thunnissen, E, Tsao, MS, Ventura, CB, Wynes, MW & Yatabe, Y 2018, Journal of Thoracic Oncology. DOI: 10.1016/j.jtho.2017.12.001

Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base
Haque, W, Verma, V, Bernicker, E, Butler, EB & Teh, BS 2017, Acta Oncologica, pp. 1-8. DOI: 10.1080/0284186X.2017.1409435

Programmed death ligand-1 (pd-l1) expression in either tumor cells or tumor-infiltrating immune cells correlates with solid and high-grade lung adenocarcinomas
Driver, BR, Miller, RA, Miller, T, Deavers, M, Gorman, B, Mody, D, Ge, Y, Barrios, R, Bernicker, E, Kim, M & Cagle, PT 2017, Archives of Pathology and Laboratory Medicine, vol 141, no. 11, pp. 1529-1532. DOI: 10.5858/arpa.2017-0028-OA

Biomarkers for selection of therapy for adenocarcinoma of the lung
Bernicker, EH, Miller, RA & Cagle, PT 2017, Journal of Oncology Practice, vol 13, no. 4, pp. 221-227. DOI: 10.1200/JOP.2016.019182

First-line immune therapy - Implications for pathologists
Miller, RA, Cagle, PT & Bernicker, EH 2016, Archives of Pathology and Laboratory Medicine, vol 140, no. 8, pp. 739-740. DOI: 10.5858/arpa.2016-0904-ED

Chemotherapy in non-small cell lung cancer: opportunities for advancement
Akhtari, M, Bernicker, EH & Teh, BS 2016, Chinese Journal of Lung Cancer, vol 35, no. 1, pp. 56. DOI: 10.1186/s40880-016-0119-x

Impact of recent developments in lung cancer on the practice of pathology
Cagle, PT, Allen, TC, Bernicker, EH, Ge, Y, Haque, A & Barrios, R 2016, Archives of Pathology and Laboratory Medicine, vol 140, no. 4, pp. 322-325. DOI: 10.5858/arpa.2015-0535-SA

Next-generation sequencing of a cohort of pulmonary large cell carcinomas reclassified by world health organization 2015 criteria
Driver, BR, Portier, BP, Mody, DR, Deavers, M, Bernicker, EH, Kim, MP, Teh, BS, Santacruz, JF, Kopas, L, Munden, RF & Cagle, PT 2016, Archives of Pathology and Laboratory Medicine, vol 140, no. 4, pp. 312-317. DOI: 10.5858/arpa.2015-0361-OA

Next-generation sequencing and immunotherapy biomarkers: A medical oncology perspective
Bernicker, E 2016, Archives of Pathology and Laboratory Medicine, vol 140, no. 3, pp. 245-248. DOI: 10.5858/arpa.2015-0287-SA

Challenges to biomarker testing for PD-1/PD-L1 checkpoint inhibitors for lung cancer
Cagle, PT & Bernicker, EH 2015, Archives of Pathology and Laboratory Medicine, vol 139, no. 12, pp. 1477-1478. DOI: 10.5858/arpa.2015-0902-ED

A new immunotherapy drug creates a watershed for the surgical pathologist's role in patient care
Cagle, PT & Bernicker, EH 2015, Archives of Pathology and Laboratory Medicine, vol 139, no. 11, pp. 1329-1330. DOI: 10.5858/arpa.2015-0901-ED

Biomarker testing in non-small cell lung cancer: A clinician's perspective
Bernicker, E 2015, Archives of Pathology and Laboratory Medicine, vol 139, no. 4, pp. 448-450. DOI: 10.5858/arpa.2014-0085-ED

Therapy
Bernicker, E, Gaur, P, Desai, S, Teh, BS & Blackmon, SH 2015, . in Diffuse Malignant Mesothelioma. Springer New York, pp. 125-139. DOI: 10.1007/978-1-4939-2374-8_7

Cardiac chloroma: Novel presentation and subsequent diagnosis with cardiac magnetic resonance imaging
Attallah, A, Cheong, BYC, Bernicker, E & Wilson, JM 2010, Texas Heart Institute Journal, vol 37, no. 2, pp. 242-243.

Unanticipated diagnoses found at autopsy in an urban public teaching hospital
Bernicker, EH, Atmar, RL, Schaffner, DL & Greenberg, SB 1996, American Journal of the Medical Sciences, vol 311, no. 5, pp. 215-220. DOI: 10.1097/00000441-199605000-00004

Case report: transverse myelitis associated with Epstein-Barr virus infection.
Caldas, C, Bernicker, E, Nogare, AD & Luby, JP 1994, American Journal of the Medical Sciences, vol 307, no. 1, pp. 45-48.